641571-44-0

Basic information

• Product Name: 2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine
• Synonyms: 2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine;6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purin-2-amine;(2R,3R,4R,5R)-2-(2-amino-6-chloro-9H-purin-9-yl)-5-((benzoyloxy)methyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate;(3R,4R,5R)-2-(2-amino-6-chloro-9H-purin-9-yl)-5-((benzoyloxy)methyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate;9H-Purin-2-amine, 6-chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-;2-Amino-6-chloro-9-(2-C-methyl)-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)]-9H-purine
• CAS NO: 641571-44-0
• Molecular Formula: C₃₂H₂₆ClN₅O₇
• Molecular Weight: 628.03114
• Mol File: 641571-44-0.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine(641571-44-0)
• EPA Substance Registry System: 2-AMino-6-chloro-9-[(2,3,5-tri-O-benzoyl- 2-C-Methyl-β-D-ribofuranosyl)]-9H-purine(641571-44-0)

Safety Data

• Hazardous Substances Data: 641571-44-0(Hazardous Substances Data)

Usage

Properties

1. Chemical Structure: 2-Amino-6-chloro-9-[(2,3,5-tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)]-9H-purine is a nucleoside analogue.
2. Molecular Formula: Not provided, but it can be derived from the given structure.
3. Molecular Weight: Not provided, but it can be calculated based on the molecular formula.
4. Functional Groups: Contains an amino group (-NH2), a chlorine atom (Cl), and multiple benzoyl groups attached to the ribofuranosyl moiety.
5. Biological Activity: Studied for potential antiviral and antitumor properties.
6. Therapeutic Potential: Investigated as a potential therapeutic agent for various diseases.
7. Role in Drug Development: Valuable tool for understanding nucleoside biological activity and for developing drugs targeting purine metabolism.

Specific Content

1. Chemical Name: 2-Amino-6-chloro-9-[(2,3,5-tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)]-9H-purine.
2. Alternative Name: Also known as 2-Amino-6-chloro-9-(N-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine.
3. Derivative: Derived from purine.
4. Nucleoside Analog: Structurally related to nucleosides.
5. Chlorine Position: Chlorine atom at position 6 of the purine ring.
6. Ribofuranosyl Moiety: Ribofuranosyl group attached to the purine base, with multiple benzoyl groups at positions 2, 3, and 5.
7. Biological Studies: Investigated for antiviral and antitumor activities.
8. Potential Therapeutic Agent: Explored for therapeutic applications in various diseases.
9. Drug Development Tool: Used for understanding nucleoside biology and developing drugs targeting purine metabolism.

This compound's structure and properties make it a promising candidate for further research and potential drug development efforts.

Upstream product

• 30361-17-2 2-methyl-2,3,5-tribenzoyl-ribonolactol 
• 7392-74-7 (3R,4R,5R)-5-((benzoyloxy)methyl)-3-methyl-2-oxotetrahydrofuran-3,4-diyl dibenzoate 
• 98-88-4 benzoyl chloride 
• 492-30-8 2-C-methyl-D-ribono-1,4-lactone 
• 10310-21-1 2-Amino-6-chloropurin 
• 10310-21-1 2-amino-6-chloropurine 
• 15397-15-6 1,2,3,5-tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose 

Downstream Products

• 915023-63-1 2-amino-6-(1-methylhydrazino)-9-(2',3',5'-tri-O-benzoyl-2'-methyl-β-D-ribofuranosyl)purine 
• 1234492-49-9 (2R,3R,4R,5R)-2-(2-amino-6-(benzylamino)-9H-purin-9-yl)-5-(benzoyloxymethyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 
• 714249-80-6 (2R,3R,4R,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 
• 1234492-50-2 (2R,3R,4R,5R)-2-(2-amino-6-(phenethylamino)-9H-purin-9-yl)-5-(benzoyloxymethyl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 
• 1384068-28-3 benzyl 2(S)-(((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy(naphthalene-1-yloxy)phosphorylamino)propanoate 
• 1384068-42-1 (2S,2'S)-benzyl 2,2'-((((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)phosphoryl)bis(azanediyl)dipropanoate 
• 1613590-23-0 C₂₆H₃₄FN₆O₉P 
• 1613590-22-9 C₄₆H₅₀FN₆O₁₀P 
• 1613590-21-8 4'-fluoro-2'-C-methyl-N²-(methoxytrityl)guanosine 
• 1613590-20-7 4'-fluoro-2',3',5'-tri-O-benzoyl-2'-C-methyl-N²-(methoxytrityl)guanosine 
• 1613590-60-5 C₄₅H₃₇FIN₅O₇ 
• 1613590-59-2 C₃₁H₂₉FIN₅O₅ 
• 1613590-58-1 4',5'-didehydro-5'-deoxy-2'-C-methyl-N²-(methoxytrityl)guanosine 
• 1613590-57-0 5'-deoxy-5'-iodo-2'-C-methyl-N²-(methoxytrityl)guanosine 

Relevant articles and documents

BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT

The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in com